Light Therapy for Psoriasis

Policy # 00131  
Original Effective Date: 03/25/2002  
Current Effective Date: 12/12/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Dermatologic Applications of Photodynamic Therapy is addressed separately in medical policy 00098.

Note: Light Therapy for Vitiligo is addressed separately in medical policy 00699.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider psoralen plus ultraviolet A (PUVA) for the treatment of severe, disabling psoriasis, which is not responsive to other forms of conservative therapy (e.g., topical corticosteroids, coal/tar preparations, and ultraviolet light), to be eligible for coverage.**

Based on review of available data, the Company may consider the use of targeted phototherapy to be eligible for coverage** for the treatment of moderate to severe psoriasis comprising less than 20% body area for which narrowband ultraviolet B (NB-UVB) or psoralen plus ultraviolet A (PUVA) are indicated.

Based on review of available data, the Company may consider the use of targeted phototherapy to be eligible for coverage** for the treatment of mild to moderate psoriasis comprising less than 20% body area that is unresponsive to conservative treatment.
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider home ultraviolet light therapy to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility may be considered for home ultraviolet light therapy when ALL of the following criteria are met:

• The device must be approved for home use by the Food and Drug Administration (FDA) and appropriate for the body surface and area treated; AND.
• The member has severe psoriasis, i.e. >10% body surface area (BSA) or if affecting hands, feet, genitalia can be <10%, with a history of frequent flares, with documented response to in-office phototherapy (as measured by BSA), for which narrowband ultraviolet B (NB-UVB) is prescribed and indicated; AND
• Long-term maintenance UV light treatment is planned and patient is unable to attend office-based treatment; AND
• The member is motivated, able to administer the treatment correctly, willing and able to keep records of treatments and attend regular follow-up visits with prescribing physician.

Note: Tanning beds are not eligible for coverage.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers targeted phototherapy as first line treatment of mild psoriasis to be investigational.*
Light Therapy for Psoriasis

Policy #  00131
Original Effective Date:  03/25/2002
Current Effective Date:  12/12/2022

Based on review of available data, the Company considers targeted phototherapy for the treatment of generalized psoriasis or psoriatic arthritis to be investigational.*

**When Services Are Considered Not Medically Necessary**
The use of home ultraviolet light therapy when patient selection criteria are not met is considered to be not medically necessary.**

**Policy Guidelines**
Disease severity in psoriasis is minimally defined by body surface area (mild psoriasis affects < 3% of body surface area, moderate psoriasis affects 3% to 10%, and severe disease affects >10% body surface area). However, lesion characteristics (eg, location and severity of erythema, scaling, induration, pruritus) and impact on the quality of life are also taken into account. For example, while a handprint is equal to approximately 1% body surface area, lesions on the hands, feet, or genitalia that cause disability may be classified as moderate-to-severe. The Psoriasis Area and Severity Index may be used as an outcome measure in clinical research. Clinical assessment of disease severity is typically qualitative.

Established treatments for psoriasis include the use of topical ointments and ultraviolet light (“light box”) treatments. Lasers and targeted ultraviolet B lamps are considered equivalent devices; targeted ultraviolet devices are comparable with ultraviolet light panels for treatment purposes. First-line treatment of ultraviolet-sensitive lesions may involve around 6 to 10 sessions (physician's office visits or at home if using a narrow-band ultraviolet B device); treatment of recalcitrant lesions may involve around 24 to 30 sessions (physician's office visits or at home if using a narrow-band ultraviolet B device). Maintenance therapy or repeat courses of treatment may be required.

During psoralen plus ultraviolet A therapy, the patient needs to be assessed on a regular basis to determine the effectiveness of the therapy and the development of adverse effects. These evaluations are essential to ensure that the exposure dose of radiation is kept to the minimum compatible with adequate control of the disease. Therefore, psoralen plus ultraviolet A is generally not recommended for home therapy.
Background/Overview

Treatment of Psoriasis

Topical therapy (eg, corticosteroids, vitamin D analogues) is generally considered first-line treatment of psoriasis, especially for mild disease. Phototherapy and systemic therapy are treatment options for patients with more extensive and/or severe disease and those who fail conservative treatment with topical agents. Phototherapy is available in various forms including exposure to natural sunlight, use of broadband ultraviolet B devices, narrowband ultraviolet B (NB-UVB) devices, targeted phototherapy, and psoralen plus ultraviolet A (PUVA). NB-UVB is an established treatment for psoriasis, based on efficacy and safety. This medical policy addresses 2 alternative treatments: targeted phototherapy, which uses ultraviolet light that can be focused on specific body areas or lesions, and PUVA.

Targeted Phototherapy

Potential advantages of targeted phototherapy include the ability to use higher treatment doses and to limit exposure to surrounding tissue. Broadband ultraviolet B devices, which emit wavelengths from 290 to 320 nm, have been largely replaced by NB-UVB devices. NB-UVB devices eliminate wavelengths below 296 nm, which are considered erythemogenic and carcinogenic, but not therapeutic. NB-UVB is more effective than broadband ultraviolet B and approaches PUVA in efficacy. Original NB-UVB devices consisted of a Phillips TL-01 fluorescent bulb with a maximum wavelength (lambda max) at 311 nm. Subsequently, an excimer (excited dimer) laser using xenon chloride (XeCl) and lamps were developed as targeted NB-UVB treatment devices; they generate monochromatic or very narrow band radiation with a lambda max of 308 nm. Targeted phototherapy devices are directed at specific lesions or affected areas, thus limiting exposure to the surrounding normal tissues. These devices may, therefore, allow higher dosages compared with a light box, which could result in fewer treatments to produce clearing. The original indication of the excimer laser was for patients with mild- to- moderate psoriasis, defined as involvement of less than 10% of the skin. Newer XeCl laser devices are faster and more powerful than the original models, which may allow the treatment of patients with more extensive skin involvement (10% to 20% body surface area).

Psoralen Plus Ultraviolet A

PUVA uses a psoralen derivative in conjunction with long-wavelength ultraviolet A (UVA) light (sunlight or artificial) for photochemotherapy of skin conditions. Psoralens are tricyclic furocoumarins that occur in certain plants and can also be synthesized. They are available in oral
Light Therapy for Psoriasis

Policy #  00131
Original Effective Date:  03/25/2002
Current Effective Date:  12/12/2022

and topical forms. Oral PUVA is generally given 1.5 hours before exposure to UVA radiation. Topical PUVA therapy refers to the direct application of the psoralen to the skin with subsequent exposure to UVA light. Bath PUVA is used in some European countries for generalized psoriasis, but the agent used (trimethylpsoralen) is not approved by the Food and Drug Administration (FDA). Paint and soak PUVA are other forms of topical application of psoralen and are often used for psoriasis localized to the palms and soles. In paint PUVA, 8-methoxypsoralen in ointment or lotion form is put directly on the lesions. With soak PUVA, the affected areas of the body are placed in a basin of water containing psoralen. With topical PUVA, UVA exposure is generally administered within 30 minutes of psoralen application.

PUVA has most commonly been used to treat severe psoriasis, for which there is no generally accepted first-line treatment. Each treatment option (eg, systemic therapies such as methotrexate, phototherapy, biologic therapies) has associated benefits and risks. Common minor toxicities associated with PUVA include erythema, pruritus, irregular pigmentation, and gastrointestinal tract symptoms; these effects generally can be managed by altering the dose of psoralen or ultraviolet light. Potential long-term effects include photoaging and skin cancer, particularly squamous cell carcinoma and possibly malignant melanoma. PUVA is generally considered more effective than targeted phototherapy for the treatment of psoriasis. However, the requirement of systemic exposure and the higher risk of adverse reactions (including a higher carcinogenic risk) have generally limited PUVA therapy to patients with more severe disease.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
In 2001, XTRAC™ (PhotoMedex), a XeCl excimer laser, was cleared for marketing by the FDA through the 510(k) process for the treatment of mild-to-moderate psoriasis. The 510(k) clearance was subsequently obtained for a number of targeted UVB lamps and lasers, including newer versions of the XTRAC system (eg, XTRAC Ultra™), the VTRAC™ lamp (PhotoMedex), the BClear™ lamp (Lumenis), and the European manufactured Excilite™ and Excilite µ™ XeCl lamps. FDA product code: FTC.

In 2010, the Levia Personal Targeted Phototherapy® UVB device (Daavlin; previously manufactured by Lerner Medical Devices) was cleared for marketing by the FDA through the 510(k) process for home treatment of psoriasis.
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

The oral psoralen product, Oxsoralen-Ultra (methoxsalen soft gelatin capsules), has been approved by the FDA and is made by Bausch Health; a generic product is also available from various manufacturers. Topical psoralen products (Oxsoralen; Valeant Pharmaceuticals) and methoxsalen hard gelatin capsules have been discontinued. Injectable methoxsalen is available but not used for psoriasis.

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Light therapy for psoriasis includes phototherapy with ultraviolet B (UVB) light boxes, targeted phototherapy, and photochemotherapy with psoralen plus ultraviolet A (PUVA). Targeted phototherapy describes the use of ultraviolet light focused on specific body areas or lesions. PUVA uses a psoralen derivative in conjunction with long-wavelength ultraviolet A light (sunlight or artificial) for photochemotherapy of skin conditions.

For individuals who have mild localized psoriasis, the evidence is lacking on the use of targeted phototherapy. Relevant outcomes are symptoms, change in disease status, quality of life (QOL), and treatment-related morbidity. The American Academy of Dermatology does not recommend phototherapy for patients with mild localized psoriasis whose disease can be controlled with topical medications. The evidence is insufficient to determine the effects of the technology on health outcomes. For individuals who have mild psoriasis that is resistant to topical medications who receive targeted phototherapy, the evidence includes small (Ns25) controlled trials (randomized controlled trials [RCTs] and non-RCTs). Relevant outcomes are symptoms, change in disease status, QOL, and treatment-related morbidity. Systematic reviews of small controlled trials in patients with moderate-to-severe psoriasis have found that targeted phototherapy has efficacy similar to whole-body phototherapy. Targeted phototherapy is presumed to be safer or at least no riskier than whole body phototherapy, due to risks of exposing the entire skin to the carcinogenic effects of UVB light. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

For individuals who have generalized psoriasis who receive PUVA, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, change in disease status, QOL, and treatment-related morbidity. The available evidence demonstrates that PUVA is more effective than narrow band-UVB phototherapy, topical steroids, or ultraviolet A without psoralens in patients with generalized psoriasis. Due to side effects, PUVA is typically restricted to more severe cases. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Supplemental Information
Practice Guidelines and Position Statements

American Academy of Dermatology – National Psoriasis Foundation
The AAD and NPF joint guidelines (2019) on the management and treatment of psoriasis with phototherapy give strong recommendations for the use of targeted UVB (Table 1).

Table 1. AAD-NPF Strength of Recommendations for Targeted UVB

<table>
<thead>
<tr>
<th>No.</th>
<th>Recommendation</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>Targeted UVB phototherapy, including excimer laser, excimer light, and targeted NB-UVB light, for use in adults with localized plaque psoriasis, for individual lesions, or in patients with more extensive disease</td>
<td>A</td>
</tr>
<tr>
<td>3.2</td>
<td>For maximal efficacy, treatment with targeted UVB phototherapy for adults with localized plaque psoriasis should be carried out 2-3 times/wk rather than once every 1-2 wk</td>
<td>A</td>
</tr>
<tr>
<td>3.3</td>
<td>The starting dose for targeted UVB phototherapy for adults with localized plaque psoriasis can be determined on the basis of the MED or by a fixed-dose or skin phototype protocol</td>
<td>A</td>
</tr>
<tr>
<td>3.4</td>
<td>An excimer laser is more efficacious than an excimer light, which is more efficacious than localized NB-UVB light for the treatment of localized plaque psoriasis in adults</td>
<td>B</td>
</tr>
</tbody>
</table>
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

| 3.5 | Recommend targeted UVB phototherapy, including excimer laser and excimer light, for use in adults with plaque psoriasis, including palmoplantar psoriasis | A |
| 3.6 | Excimer laser may be combined with topical corticosteroids in the treatment of plaque psoriasis in adults | B |
| 3.7 | Recommend excimer laser in the treatment of scalp psoriasis in adults | B |

Table adapted from Elmets et al (2019).

NB-UVB: narrowband ultraviolet B; UVB: ultraviolet B.

The guidelines state of home NB-UVB therapy that evidence shows similar results regarding efficacy, quality of life, and side effects between patients with mild-to-severe psoriasis who received home treatments and those who received treatments at hospitals. In addition, home treatment was found to significantly lessen the burden on patients who had to travel to a phototherapy center.

**American Academy of Dermatology**
The American Academy of Dermatology (2010) guidelines on the management of psoriasis recommended that patients with psoriasis who are compliant could, under dermatologist supervision, be considered appropriate candidates for home ultraviolet B therapy. Targeted phototherapy was recommended for patients with mild, moderate, or severe psoriasis with less than 10% involvement of the body surface area. Systemic psoralen plus ultraviolet A was indicated in adults with generalized psoriasis resistant to topical therapy.

**National Psoriasis Foundation**
The National Psoriasis Foundation (2017) published consensus guidance based on a task force review of the literature on the treatment for psoriasis involving skinfolds (inverse or intertriginous) psoriasis. The treatment guidance for intertriginous or genital psoriasis stated: "...here is anecdotal evidence demonstrating the strong clinical efficacy of biologic treatment; with limited knowledge on the effects of biologics on intertriginous or genital psoriasis." The guidance on inverse psoriasis is provided in Table 2.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 8 of 17
Table 2. Recommendations on Treatment of Inverse Psoriasis

<table>
<thead>
<tr>
<th>Line of Therapy</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line therapy</td>
<td>Low potency topical steroids for periods less than 2-4 wks</td>
</tr>
<tr>
<td></td>
<td>Other topical therapies to consider are tacrolimus, pimecrolimus, calcitriol,</td>
</tr>
<tr>
<td></td>
<td>or calcipotriene to avoid steroid side effects with long-term treatment</td>
</tr>
<tr>
<td>Second- and third-line therapies</td>
<td>Antimicrobial therapy, emollients, and tar-based products</td>
</tr>
<tr>
<td></td>
<td>Axillary involvement can be treated with botulinum toxin injection to</td>
</tr>
<tr>
<td></td>
<td>reduce perspiration and inhibit inflammatory substance release</td>
</tr>
<tr>
<td></td>
<td>Excimer laser therapy or systemic agents</td>
</tr>
</tbody>
</table>

The National Psoriasis Foundation (2017) also published recommendations based on a review of the literature on the treatment for psoriasis in solid organ transplant patients. Because organ transplant patients are excluded from randomized controlled trials, there are limited data. The recommendations were based on case series (see Table 3).

Table 3. Recommendations on Treatment of Psoriasis for Solid Organ Transplant Patients

<table>
<thead>
<tr>
<th>Line of Therapy</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line therapy for mild-to-moderate psoriasis</td>
<td>Topical therapy</td>
</tr>
<tr>
<td>First-line therapy for moderate-to-severe psoriasis</td>
<td>• Acitretin with narrowband ultraviolet light or</td>
</tr>
<tr>
<td></td>
<td>• Narrowband ultraviolet light or</td>
</tr>
<tr>
<td></td>
<td>• Acitretin</td>
</tr>
<tr>
<td>Second-line therapy</td>
<td>Increasing the current anti-rejection drug dose</td>
</tr>
<tr>
<td>Severe psoriasis or refractory cases</td>
<td>Systemic or biologic therapies</td>
</tr>
</tbody>
</table>
U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
Ultraviolet light treatment is covered; targeted phototherapy is not specifically mentioned. There is no national coverage determination on psoralen plus ultraviolet A.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 4.

Table 4. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03180866(^a)</td>
<td>Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis</td>
<td>32</td>
<td>Mar 2018 (unknown; updated 06/08/17)</td>
</tr>
<tr>
<td>NCT02999776(^a)</td>
<td>An Observer Partially-blinded, Lesion-randomized, Intra-patient Controlled, 3-arm, Phase I Study to Assess Safety and Efficacy of Laser-assisted Topical Etanercept Administration in Patients With Mild to Moderate Plaque Psoriasis</td>
<td>30</td>
<td>Jun 2018 (unknown; updated 12/21/16)</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02294981</td>
<td>A Randomized Clinical Trial to Determine Whether a Novel Plaque-based Dosimetry Strategy Can Improve the Speed of Response to Treatment in Patients With Plaque Psoriasis (Photos)</td>
<td>30</td>
<td>Jun 2017 (terminated; updated 12/10/18)</td>
</tr>
</tbody>
</table>

\(^a\) Updated

\(^b\) Terminated
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.
b Protocol was changed to make it easier for treating doctors. No safety concerns.

References
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022


Policy History
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022
03/21/2002 Medical Policy Committee/ review
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

03/25/2002       Managed Care Advisory Council approval.
06/24/2002       Format revision. No substance change to policy
03/08/2004       Medical Director review
03/29/2004       Managed Care Advisory Council approval
03/01/2005       Medical Director review
03/15/2005       Medical Policy Committee review
04/04/2005       Managed Care Advisory Council approval
11/02/2005       Medical Director review
11/15/2005       Medical Policy Committee review. Format revision. FDA approval information added. Updated coverage eligibility to include use of UVB in treatment of psoriasis.
01/26/2006       Quality Care Advisory Committee approval
05/03/2006       Medical Director Review
05/17/2006       Medical Policy Committee Review. UVB has been removed from policy.
04/04/2007       Medical Director review
04/18/2007       Medical Policy Committee approval. Coverage eligibility unchanged.
11/07/2007       Medical Director review
11/15/2007       Medical Policy Committee approval. Replaced policy including title changed from Ultraviolet Light, Including Laser Therapy, for Skin Conditions. Coverage eligibility unchanged.
11/05/2008       Medical Director review
11/18/2008       Medical Policy Committee approval. Targeted phototherapy for the first line treatment of mild psoriasis and generalized psoriasis or psoriatic arthritis is now considered to be investigational.
11/12/2009       Medical Policy Committee approval
11/04/2010       Medical Policy Committee review
11/03/2011       Medical Policy Committee review

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 13 of 17
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

11/01/2012 Medical Policy Committee review
11/28/2012 Medical Policy Implementation Committee approval. Title changed from Targeted Phototherapy for Psoriasis to Light Therapy for Psoriasis. Added new eligible for coverage statement. “PUVA for the treatment of severe, disabling psoriasis, which is not responsive to other forms of conservative therapy (e.g., topical corticosteroids, coal/tar preparations, and ultraviolet light), is considered to be eligible for coverage.”

11/07/2013 Medical Policy Committee review
11/20/2013 Medical Policy Implementation Committee approval. No change to coverage.
11/06/2014 Medical Policy Committee review
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/29/2015 Medical Policy Committee review
11/16/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2016 Medical Policy Committee review
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
11/02/2017 Medical Policy Committee review
11/08/2018 Medical Policy Committee review
02/06/2019 Coding update
11/07/2019 Medical Policy Committee review
11/13/2019 Medical Policy Implementation Committee approval. Added “When Services May Be Eligible for Coverage” and a “When Services Are Not Medically Necessary” sections for home ultraviolet light box therapy.
11/05/2020 Medical Policy Committee review
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

11/11/2020  Medical Policy Implementation Committee approval. Removed “box” from ultraviolet light box therapy to read ultraviolet light therapy in the eligible for coverage and not medically necessary statements. Coverage eligibility unchanged.

11/04/2021  Medical Policy Committee review
11/03/2022  Medical Policy Committee review

Next Scheduled Review Date: 11/2023

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>96912, 96913, 96920, 96921, 96922</td>
</tr>
<tr>
<td>HCPCS</td>
<td>E0691, E0692, E0693, E0694</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>L40.0-L40.9</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
Light Therapy for Psoriasis

Policy # 00131
Original Effective Date: 03/25/2002
Current Effective Date: 12/12/2022

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.